eisai pharmaceuticals
Eisai’s New Treatment For Alzheimer’s Disease Receives FDA Fast Track Approval
The US Food and Drug Administration has granted Fast Track designation for the development of an enzyme that could potentially slow the progression of Alzheimer’s Disease.
Eisai Provides Free Antiparasitic Tablets To Indonesia
Eisai has provided 151 million free diethylcarbamazine citrate tablets to the government of Indonesia for the treatment of elephantiasis.
DNDi & Eisai To Develop Treatment For Eumycetoma
Eisai and Drugs for Neglected Diseases initiative plan to run clinical trials for the anti-fungal drug Fosravuconazole.
Eisai & Merck To Test Combination Cancer Drugs
Eisai and Merck have entered a partnership to test combinations of their patented drugs on breast and other cancers.
Eisai Launches Liver Cirrhosis Drug In The Philippines
The drug for treating liver cirrhosis-associated hypoalbuminemia is also awaiting clinical trials in China.
Eisai & Zeria To Develop Gastic Acid Drug
Eisai grants Zeria the right to manufacture E3710, a proton pump inhibitor than can be used to treat gastric acid-related diseases.
Eisai Completes Phase III Trial For Epilepsy Drug
The Phase III clinical trial for Eisai's in-house developed AMPA receptor antagonist Fycompa® has met its primary endpoints in patients with severe seizures.
Eisai & KRI Open New Research Facility In Kobe
The new facility located in the Kansai International Strategic Innovation Zone will focus on developing biologic therapies.
New Alzheimer’s Drugs Developed By Eisai & Biogen Idec
Eisai and Biogen Idec are developing two new Alzheimer's drugs at Phase II clinical trials, E2609 and BAN2401.
Eisai, Uni Of Tsukuba To Find Treatments For IBD
The private-public partnership between Eisai and the University of Tsukuba will focus on developing drugs and diagnostics for inflammatory bowel disease.
